Interleukin-11 (IL-11) is a pleiotropic cytokine with biological effects on different cell types in a variety of tissues. The functional activities of IL-11 are associated with activation of the gp130 signal-transduction unit and involve hematopoietic, immunomodulatory and epithelial effects . Since recombinant human IL-11 (rhIL-11) has been manufactured by DNA technology in Escherichia coli, treatment of chronic gastrointestinal inflammation became the focus of preclinical and clinical studies investigating the effect of subcutaneously administered rhIL-11 on gastrointestinal inflammation and injury. RhIL-11 has been found to suppress inflammation by reducing the expression of pro-inflammatory mediators such as INF-γ, TNF-α, IL-1β, IL-6 and iNOS in the colon of HLA-B27 rats with chronic colitis (Peterson et al., 1998) . In addition to having an anti-inflammatory effect, rhIL-11 was found to be an epithelial growth factor increasing survival after cytoablative therapy and irradiation in mice by preventing apoptosis, promoting recovery of small intestinal epithelial cells and restoring the intestinal mucosal barrier (Du et al., 1994; Orazi et al., 1996) . In vitro studies indicate that IL-11 modulates epithelial dynamics in untransformed intestinal epithelial cells, suggesting that IL-11 may be part of the normal growth control and repair in the intestinal epithelium (Booth and Potten, 1995) .
Although the effects of rhIL-11 on mucosal inflammation and histology in animal models of colitis have been well documented (Keith et al., 1994; Qiu et al., 1996) , few studies have investigated the possible effects of rhIL-11 on intestinal transport and contractility. Subcutaneous This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 20, 2003 as DOI: 10.1124 at ASPET Journals on October 2, 2017 jpet.aspetjournals.org Downloaded from JPET #58701 5 administration of rhIL-11 was associated with partial normalization of the colonic smooth muscle dysfunction in a rabbit model of colitis (Depoortere et al., 2000) , and normalization of basal transepithelial potential difference (PD) in mucosal sheets isolated from the jejunum of HLA-B27 rats with chronic inflammatory disease .
Furthermore, the oral treatment of HLA-B27 rats with a new enteric-coated formulation of rhIL-11 reversed the symptoms of colitis and normalized intestinal muscle function. When rhIL-11 was applied directly to isolated intestinal mucosal sheets studied in modified Ussing chambers, it caused a reduction of transepithelial PD (Greenwood-Van Meerveld et al., 2001) , suggesting that IL-11 receptors expressed on the luminal surface of intestinal epithelial cells (Grosfeld et al., 1999; Opal et al., 2003) may be functionally activated. Such epithelial IL-11 receptors are likely to represent a site of specific interaction with orally administered rhIL-11. This suggestion is supported by a recent study (Ropeleski et al., 2003) demonstrating that IL-11 induces the expression of heat shock protein 25 in intestinal epithelial cells, which presents a cytoprotective mechanism against oxidative stress and increases epithelial viability. However, it remains unclear whether oral treatment with rhIL-11 can normalize abnormalities in intestinal epithelial transport.
The goal of the present study was to examine the effect of oral treatment with rhIL-11 on abnormalities in colonic electrogenic transport in HLA-B27 transgenic rats with chronic colitis.
This article has not been copyedited and formatted. The final version may differ from this version. HLA-B27 transgenic rats were used as a model of colitis because they develop spontaneous chronic inflammation of the gastrointestinal tract that closely resembles inflammatory bowel disease (IBD) in humans (Hammer et al., 1990) . Non-transgenic Fisher 344 (F344) rats served as controls. The rats were treated with an oral formulation of rhIL-11, that was specifically designed to pass through the stomach and deliver rhIL-11 within the lumen of the intestine without detectable systemic absorption (Tseng et al., 2000) . Electrogenic mucosal transport was studied in modified Ussing chambers by measuring basal short circuit current (Isc) and changes in epithelial secretion and transepithelial electrical resistance in colonic mucosal sheets. The therapeutic effect of oral dosing of rhIL-11 (500 µg/kg given on alternate days for 2 weeks) was followed in vivo as changes in stool character during the treatment period, while tissue myeloperoxidase (MPO) activity and mucosal transport were measured in vitro in colonic preparations isolated at the end of the treatment. 
METHODS

Experimental animals.
Male Fischer 344 rats genetically engineered to express human HLA-B27 and β 2 -microglobulin were used as a model of chronic inflammation reminiscent of human inflammatory bowel disease (IBD). Age-matched non-transgenic Fisher 344 rats were used as controls. HLA-B27 transgenic rats (n=12) or Fisher 344 rats (n=12) were purchased from Taconic (Germantown, New York) at 10-12 weeks of age and were housed in the animal facility until the age 36-40 weeks. All rats were housed in individual cages at room temperature of 21 o C, standard humidity and a 12-h light/dark cycle. Conventional laboratory rodent chow and tap water were provided ad libitum.
The V.A. Animal Care and Use Sub-Committee, Oklahoma City, Oklahoma approved the experimental procedures used in the study.
Treatment with rhIL-11.
The study was designed to investigate whether oral treatment with enteric-coated rhIL-11 multiparticles or placebo can improve the impaired mucosal ion transport in the colon of HLA-B27 transgenic rats with chronic colitis. The dose and time-course of rhIL-11 treatment were selected from a previous study (Greenwood et al., 2001) showing normalization of mucosal histology and a reversal of intestinal smooth muscle dysfunction in the colon of HLA-B27 rats. The formulation of rhIL-11 for oral administration consisted of multi-particles coated with an enteric This article has not been copyedited and formatted. The final version may differ from this version. polymer that dissolves at pH >5.5, thus ensuring that the coating is insoluble in the stomach but does dissolve in the small intestine. The test article contained approximately 1.0 mg rhIL-11 per 100 mg/multi-particles. The control article (placebo) consisted of enteric polymer coated sucrose multi-particles. A daily oral dose of enteric-coated rhIL-11 or placebo was given to the animals at 8 -9 A.M. every other day during 2 weeks. The rats were euthanized 3 h after receiving the last oral dose and the colon was isolated for in vitro investigation. The rats were randomly assigned to four groups that received different treatment as follows: a test group of HLA-B27 transgenic rats (n=6) treated with enteric-coated rhIL-11; a placebo-treated group of HLA-B27 transgenic rats (n=6) receiving enteric-coated sucrose multi-particles; a test group of nontransgenic F344 rats (n=6) treated with enteric-coated rhIL-11; and a placebo-treated group of non-transgenic F344 rats (n=6) receiving enteric-coated sucrose multi-particles.
Evaluation of stool character
The stool character was observed and scored daily during the two weeks of treatment.
Specifically, the stool was scored as 0 for normal, 1 for soft with formed pellets, 2 for soft with no pellet formation and 3 for watery diarrhea. Average daily scores were calculated for each experimental group. This article has not been copyedited and formatted. The final version may differ from this version. 
Myeloperoxidase (MPO) activity.
MPO is a granule-associated peroxidase primarily contained in polymorphonuclear neutrophils infiltrating the inflamed tissue. MPO activity, measured in colonic tissue was considered a biochemical marker of inflammation. Tissue samples (150-200 mg) from both HLA-B27 and F344 rats were collected from the mid to proximal colon isolating small segments from regions adjacent to those used for the Ussing chamber preparations. Full thickness colonic samples were immediately frozen in liquid nitrogen and stored at -80 o C. The samples were analyzed simultaneously as described previously (Venkova et al., 2000) . Briefly, homogenization and MPO extraction was performed in hexadodecyl-trimethylamonium bromide (HTAB) phosphate buffer (pH 6). MPO activity was measured in 10 µl samples using 3,3',5,5'-tetramethylbenzidine TMB Microwell Peroxidase Substrate System (Sigma Chem. Co., St.
Louis, MO) and horseradish peroxidase (HRP) as a relative standard. MPO activity was expressed as equivalent to the activity of the relative standard (ng of HRP) converting the same amount of TMB substrate for 10 min at room temperature. Mean values are given in ng normalized per g wet weight of the tissue.
Ussing chamber experiments
The colon was harvested, the luminal contents were removed by washing with modified Krebs 
Paracellular electrical resistance
Both paracellular and transcellular pathways contribute to the transepithelial electrical resistance of a mucosal sheet measured in the Ussing chamber. To determine the paracellular resistance we used the approach of Parkos et al. (1992) and Riegler et al. (1999) . The response to SP was selected as a model system to investigate the relationship between Isc and conductance because SP is known to induce a transient increase in Isc without altering paracellular resistance (Reigler et al., 1999) . In our experiments transepithelial PD and Isc were measured at different time points during the ascending (0-2 min) and descending (2-20 min) phase of the response to SP (1 µM) applied to the serosal side. Electrical conductance (mS/cm 2 ) was calculated for each timepoint and was plotted against the Isc (µA/cm 2 ). Separate plots were constructed for the ascending and descending phase of the SP response. The value of conductance at the x-axis intercept (Isc equals zero) was determined by linear regression analysis of the plots for the ascending and descending phase of the SP response. The paracellular resistance was calculated as reciprocal of the conductance at zero Isc (resistance (Ω/cm 2 ) = 1/conductance (mS/cm
Solutions and drugs
The experiments were performed using modified Krebs bicarbonate solution of the following composition (in mM): NaCl 120, KCl 6, MgCl 2 1.2, NaH 2 PO 4 1.2, CaCl 2 2.5, NaHCO 3 14.4 and glucose 11.5. The solution was continuously gassed with 95% O 2 and 5% CO 2 (vol/vol) and the pH at room temperature ranged from 7.2 to 7.3. Carbamylcholine chloride (carbachol), atropine sulfate, guanethidine and substance P were obtained from Sigma-Aldrich Chemical Co. (St.
Louis, MO) and were dissolved in distilled water. All drugs were added to the baths in volumes less that 1% of the total bath volume. The enteric-coated formulation of rhIL11 and the entericcoated sucrose multiparticles (placebo) were provided by Wyeth Research (Cambridge, MA).
Statistical Analysis
The data presented in the study are mean ± SEM of 6 animals for each experimental group. In the Ussing chamber experiments 4-6 values from individual mucosal sheets were obtained from each rat. MPO activity was measured in triplicate in single tissue samples isolated from each animal.
Regression analysis of complete concentration-response curves was used to calculate the concentration of carbachol causing 50% of the maximal effect (EC 50 ) and the 95% CI.
Homogeneity of variances i.e. no significant difference between SD among the groups was verified using Bartlett's test. Comparison between multiple groups was made using ordinary oneThis article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Effect of rhIL-11 treatment on stool character
With the advance of age, all HLA-B27 rats used in the study spontaneously developed colitis.
The symptoms of loose stool without pellet formation alternating with long-lasting episodes of watery diarrhea became evident at the age of 22-28 weeks and persisted for 4-6 weeks before initiation of the rhIL-11 or placebo treatment. At the beginning of rhIL-11 or placebo treatment, the stool consistency scores were 2 and 3 in all HLA-B27 rats. In contrast, the age-matched F344 rats appeared to be healthy and had normal stools (stool consistency score 0). In HLA-B27 rats, oral treatment with rhIL-11 caused a significant improvement is stool consistency compared to the lack of effect in the placebo treated group. At the end of the treatment period the stool character observed in the group of HLA-B27 rats receiving rhIL-11 was changed towards normal i.e. soft but normally formed pellets (score 1 and 2), while the group of HLA-B27 rats receiving placebo showed no change in the pattern of chronic diarrhea (score 2 and 3). The groups of healthy F344 rats receiving either rhIL-11 or placebo treatment had normal stools throughout the treatment period (score 0).
Effect of rhIL-11treatment on colonic MPO activity
The activity of MPO was measured in whole tissue samples isolated from the colon of HLA-B27 transgenic rats or F344 rats receiving either rhIL-11 or placebo treatment. As shown in MPO activity was significantly higher in the colon of HLA-B27 rats receiving placebo compared to placebo-treated healthy F344 rats. Treatment with rhIL-11 significantly reduced MPO activity in the colon of HLA-B27 rats, while having no significant effect in the colon of F344 rats.
However, the decreased level of MPO activity observed in the HLA-B27 group treated with rhIL-11 was still significantly higher compared to the levels of MPO measured in the F344
groups.
Effect of rhIL-11 treatment on basal electrogenic transport
Basal electrogenic transport in the isolated colonic mucosal sheets was characterized by 
Effects of rhIL-11 treatment on SP-induced response and paracellular mucosal resistance
A set of experiments was designed to study the secretory response to SP (1 µM) and to determine the paracellular resistance during the ascending and descending phase the response. The increase in Isc induced by SP in mucosal preparations isolated from HLA-B27 rats was of lower amplitude compared to F344 rats, while there was no significant difference between the SPinduced increase in Isc in placebo-treated or rhIL-11 treated rats (Figure 3 A,B) . Specifically, the maximal Isc induced by SP in the colon of HLA-B27 rats was 61±9 µA/cm 2 for the placebotreated rats and 67±7 µA/cm 2 for the rhIL-11-treated rats, while the maximal response measured in F344 rats was significantly higher (p<0.01), reaching 166±16 µA/cm 2 and 143±25 µA/cm 2 , respectively. Concurrent with the increase in Isc, SP induced a decrease in transepithelial resistance in the colon of F344 rats, while no substantial changes of resistance were observed following SP administration to the colonic mucosa from HLA-B27 rats (Figure 3 C,D) . The Isc and conductance measured during the ascending and descending phase of the SP effect were used to estimate paracellular resistance. In accordance with previous studies (Reigler et al.,1999) we found that in each group the paracellular resistance calculated for the ascending and descending phase of the SP response had the same value (Table 1) indicating that paracellular resistance is not affected by changes in transepithelial conductance driven by active Cl -secretion.
By comparing the results found in colonic mucosa from placebo-treated HLA-B27 rats with these in preparations from placebo-treated healthy F344 rats we defined that paracellular resistance is lower in the HLA-B27 rats. Treatment of HLA-B27 rats with rhIL-11 resulted in a significant increase in paracellular resistance to values that are not different from these in placebo-treated F344 rats (Table 1) .
Effect of rhIL-11 treatment on mucosal responses to EFS
In a separate series of experiments EFS (0.5ms, 5 Hz) was applied to the mucosal sheets to induce a maximal secretory response measured as an increase in Isc. The response to EFS was completely inhibited by TTX (1 µM) indicating that it is due to intramural nerve stimulation (data not shown). Colonic mucosal sheets isolated from HLA-B27 or F344 rats treated with either rhIL-11 or placebo were studied and mean values of the maximal increase in Isc induced by EFS were calculated for each group. As illustrated in Figure 4A , the EFS-induced increase in
Isc was significantly lower in mucosal sheets isolated from placebo-treated HLA-B27 rats compared to placebo-treated F344 rats. However, when HLA-B27 rats received rhIL-11 treatment, the response to EFS was significantly increased and was no longer different from the 
Effect of rhIL-11 treatment on carbachol-induced Isc
The increase in Isc induced by activation of muscarinic cholinoceptors was studied by following the response to carbachol applied to the serosal bathing solution. Cumulative administration of increasing concentrations of carbachol resulted in a concentration-dependent increase in Isc until a maximal response was achieved ( Figure 5 ). The maximal carbachol-induced response in mucosal sheets isolated from placebo-treated HLA-B27 rats was of significantly lower amplitude compared to placebo-treated F344 rats (28±6 µA/cm 2 vs. 98±10 µA/cm 2 , p<0.001). Treatment with rhIL-11 did not cause a significant change in the maximal response to carbachol in either the HLA-B27 or F344 rats. The EC 50 values calculated from the concentration-response curves (Table 2) showed that mucosal sheets isolated from placebo-treated HLA-B27 rats yielded an EC 50 that was significantly higher compared to placebo-treated F344 rats. However, in both This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
Intestinal inflammation in patients with IBD is associated with loss of tolerance to resident enteric bacteria (Duchmann et al., 1995) , activation of immune cells, and infiltration of leukocytes coordinated by the production of chemokines, proinflammatory monokines, and Th1 cytokines (Fiocchi, 1998) . Therapies based on the antagonist activity of antibodies against TNFα have recently been introduced as an alternative to steroids in the treatment of IBD (Sandborn and Hanauer, 2002) . In this respect, the potential therapeutic use of rhIL-11 presents an unique approach to the treatment of IBD combining the effects of a multipotent protein of mesenchymal origin (Dorner et al., 1997) acting both as an anti-inflammatory cytokine and as an epithelial growth factor restoring the integrity of intestinal epithelium. Furthermore, experiments performed in vitro using specimens of human colonic mucosa (Valenick et al., 1998) have indicated that rhIL-11applied to the mucosal or serosal solution prevents the typical increase in mucosal permeability induced by C. difficile toxin, thus suggesting a topical protective effect of IL-11. In clinical studies, weekly subcutaneous injection with rhIL-11 was safe and effective in inducing remission in patients with active Crohn's disease (Sands et al., 1999; Sands et al., 2002) . In addition rhIL-11 was found to reduce bacteraemia in patients undergoing chemotherapy by preserving mucosal integrity in the gastrointestinal tract (Ellis et al., 2003) .
This article has not been copyedited and formatted. The final version may differ from this version. The present study investigated the ability of a new formulation for local delivery of rhIL-11 into the intestine to suppress colonic inflammation and reverse epithelial dysfunction in a rat model of chronic colitis. This strategy has the advantage that rhIL-11 delivery may be directly targeted to the site of inflammation. A previous study (Tseng et al., 2000) indicated no measurable levels of systemic rhIL 11 in normal Sprague Dawley or Fisher rats or in diseased HLA-B27 transgenic rats. Moreover, to determine whether a small amount of rhIL-11 has reached the portal blood and has been subsequently removed by first-pass hepatic uptake, the gene expression of hepatic acute phase proteins was investigated. The results found no changes in the expression of rhIL-11 responsive hepatic genes indicating no hepatic or systemic exposure to the cytokine following oral administration of the formulation. Experiments following the distribution of radiolabeled enteric coated rhIL-11 confirmed intraluminal levels of rhIL-11 in the terminal ileum and proximal colon (unpublished data, Wyeth Research) Taken together these results imply that the enteric coated formulation designed for oral administration of rhIL-11 may provide topical action while preventing hematopoetic effects associated with systemic rhIL-11 administration.
The use of HLA-B27 transgenic rats co-expressing the human major histocompatibility class I allele HLA-B27 and β 2 -microglobulin provided a model of T-cell-dependent chronic multiorgan inflammation that is reminiscent of B27-associated spondyloarthropathy and IBD in humans (Hammer et al., 1990) . Our results confirmed that a two-week therapy of either oral In accordance with other studies (Tseng et al., 2000) indicating no measurable levels of rhIL-11 in F344 or diseased HLA-B27 rats following oral administration of the enteric coated rhIL-11 formulation, our data strongly suggests that local mechanisms of interaction between rhIL-11 and epithelial and immune cells and/or submucosal neurons within the intestinal wall can promote healing of HLA-B27 associated colitis.
Epithelial pathophysiology during inflammation is characterized by increased permeability and abnormal secretion and/or absorption of water and electrolytes (Santos and Perdue, 1998) .
Therefore, understanding the clinical relevance of these findings is important for the development of new approaches in the therapy of immune-regulated intestinal diseases. In the present experiments treatment of HLA-B27 rats with chronic colitis with rhIL-11 resulted in a significant increase in basal transepithelial resistance, which reached a value not significantly different from that in placebo-treated healthy F344 rats. In contrast, rhIL-11 treatment had no effect on basal Isc implying that rhIL-11 is more likely influencing the passive transport of electrolytes rather than improving the active transport driven by ATP-dependent Na + /K + exchange in the enterocytes. Such an assumption is supported by our observation that the increase in Isc induced by either SP or carbachol, caused by the active secretion of Cl -ions (Kuwahara and Cooke, 1990) , remained impaired in the colon of HLA-B27 rats following the treatment with rhIL-11. The passive transport of electrolytes and water is driven by This article has not been copyedited and formatted. The final version may differ from this version. electrochemical concentration gradients and involves both a transcellular and a paracellular route. In our experiments, the low paracellular resistance defined in placebo-treated HLA-B27 rats was significantly increased in HLA-B27 rats treated with rhIL-11. The low paracellular resistance in the colon of HLA-B27 rats agrees with the findings of Schmitz et al. (1999) in colonic mucosa from patients with ulcerative colitis showing that alterations in the structure of tight junctions contribute to the barrier defect. It has also been found that increased colonic ion permeability in ulcerative colitis is associated with epithelial leaks defined as dramatic changes in epithelial conductance measured at sites of apoptotic activity (Gitter et al., 2001 ). In the context of these findings, our results suggest that a paracellular leak that contributes to diarrhea in colitis may be 'repaired' by rhIL-11. Moreover, the interaction between orally administrated rhIL-11 and the colonic epithelium in the HLA-B27 rats is likely to include a rhIL-11-induced decrease in the apoptosis of intestinal epithelium crypt cells as reported by Orazi and colleagues (1996) . Most recently, it has been found that activation of IL-11 receptors expressed by rat intestinal epithelial cells involves up-regulation of inducible heat-shock protein protecting the enterocyte from local oxidant injury (Ropeleski et al., 2003) . Finally, an unknown effect of rhIL-11 on mucosal permeability which is independent of the healing of inflammation is likely to contribute to the increased transepithelial resistance found in colonic mucosal sheets isolated from healthy F344 rats treated with rhIL-11 compared to placebo-treated F344 rats.
This article has not been copyedited and formatted. The final version may differ from this version. In a separate series of experiments we investigated the effect of oral treatment with rhIL-11 on neurally mediated secretion induced by EFS of enteric nerve terminals confined in the mucosa and submucosal plexus in muscle-stripped mucosal preparations. As described previously in guinea pig distal colon (Javed and Cooke, 1992) , electrical stimulation of submucous neurons induces secretion of Cl -ions that can be measured as an increase in Isc. Stimulation at 5 Hz has been associated with excitation of cholinergic pathways since it was found to induce the release of acetylcholine. In our experiments we investigated the effects of rhIL-11 treatment on maximal responses to EFS (5 Hz, 0.5 ms) induced in colonic mucosal sheets isolated from HLA-B27 or F344 rats. The Isc induced in colonic sheets from placebo-treated HLA-B27 rats was significantly lower compared to placebo-treated F344 rats. A similar impairment of the neurally mediated increase in Isc was present at NANC conditions, suggesting that the decrease in neurally mediated responses is not limited to an inflammatory damage of cholinergic neurons and may involve NANC nerves. Furthermore, we found that treatment with rhIL-11 caused an increase in EFS-induced Isc increasing both cholinergic and NANC components of the responses to levels that were not significantly different from those defined for F344 rats. A possible reason for this effect could be the ability of rhIL-11 to reduce the expression of proinflammatory cytokines which are closely related to enteric nerve dysfunction (Collins et al, 1989; Main et al., 1993) . A recent study (Galeazzi et al., 2000) changes. In addition, the increase in EFS response may reflect a long-lasting post-inflammatory modulation of secretomotor responses characterized by a switch from predominantly cholinergic to NANC excitation (Venkova et al., 1999) . Similar to EFS-induced responses, the maximal increase in Isc evoked by carbachol or exogenous SP was lower in mucosal sheets isolated from placebo-treated HLA-B27 rats with colonic inflammation compared to healthy F344 rats. In contrast to the significant improvement of EFS-induced responses, the treatment of HLA-B27 rats with rhIL-11 did not significantly change the carbachol or SP-induced increase in Isc.
Similar hyporesponsiveness to carbachol and other secretagogues has been demonstrated in animal models of colitis induced by trinitrobenzenesulfonic acid and it has been found to extend for up to 12 weeks beyond the acute phase of the inflammatory response (Bell et al., 1995; MacNaughton et al., 1998) . In the same model of colitis, prolong epithelial dysfunction persisted when the rats were treated with dexamethasone causing a normalization of Isc responses to EFS while the responses to carbachol remained significantly depressed (Asfaha et al., 1999) .
Although the mechanisms underlying rhIL-11 effect on EFS remain unclear, it is reasonable to suggest that a post-inflammatory remodeling of enteric neurons and a direct effect of rhIL-11 on post-synaptic receptors may partially compensate for the hyporesponsiveness of epithelial cells to secretagogues. The shift of the EC 50 for carbachol to lower concentrations following treatment with rhIL-11 is one piece of evidence pointing in this direction, however specific experiments are required to elucidate the effect.
This article has not been copyedited and formatted. The final version may differ from this version. In conclusion, our findings are the first to indicate that oral rhIL-11 therapy is associated with suppression of mucosal inflammation and a concomitant improvement of epithelial resistance and neurally mediated secretion in a model of chronic HLA-B27 colitis. The results suggest that intestinal delivery of rhIL-11 targeting the mucosa while avoiding hepatic or systemic exposure to the cytokine may provide a new approach for the treatment of human IBD. Furthermore, when considered in view of previous findings (Booth and Potten, 1995) showing that IL-11 may regulate the normal growth of intestinal epithelium, while having no effect on tumor cell lines, our results support the assumption that rhIL-11 may be useful as an adjuvant to cytotoxic cancer therapies.
This article has not been copyedited and formatted. The final version may differ from this version. and guanethidine (10 µM) to obtain NANC responses (B). Data are mean ± SEM for colonic preparations isolated from N=6 rats for each group. Differences between means were analyzed for statistical significance at p<0.05 using one-way ANOVA followed by Bonferroni post test.
a-significantly different from placebo-treated HLA-B27 rats; b-significantly different from placebo-treated F344 rats; c-significantly different from rhIL-11-treated F344 rats. Data are mean ± SEM from N=6 rats for each group and the 95% CI are given in parenthesis.
There was no significant difference between the paracellular resistance estimated from the upward and downward phase of the response to SP for each group. One-way ANOVA of the data for each phase showed that the variation among group means is significant (P<0.0001).
Differences between groups are indicated as follows: a -significantly different from placebo- The data are derived by regression analysis of the linear portion of the concentration-response curves and 95% CI are given in parenthesis. 
